SFEBES2026 Poster Presentations Bone and Calcium (28 abstracts)
An audit of management of Vertebral Fractures detected and reported from lateral CXR using AI technology in a tertiary Oncology centre
Hattie Rogerson - Bevan 1,2,3 , Claire Higham 1 , Nicola Chesman 4 , Claire Barker 3 , Fenella Wong 3 , Faye Frost 3 , Sarah Simpson 3 & Lauren Berger 3
1Department of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; 2Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; 3Department of Radiology, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; 4Department of Supportive Oncology, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
Vertebral Fractures (VF) are common (10-15% on routine imaging), associated with significant morbidity, and strongly predict further fractures. Up to 70% of VF don’t come to medical attention. Of VFs reported there are low levels of subsequent action to improve bone health. AI techniques to detect VF on imaging (lateral CXR, CT) are available and undergoing evaluation by NICE. A project using AI technology to detect VF on lateral CXR is underway in our institution. This audit aimed to review the impact of reporting VF detected by AI on lateral CXR. Patients with a VF (n = 173) detected by Al on CXR within a 3 month period (Oct-Dec2024) were identified (audit registered with local QICA committee). Data from n = 80 were analysed (n = 35/80 new VF) using local EPR system. Demographic data, CXR indication, oncology history (known metastatic disease), ECOG performance score and fracture management were collected into a pseudo-anonymised EXCEL spreadsheet. Mean(+/-SD) age 67(+/-10)yrs (43Female), Cancer diagnoses: Lung(n = 21), haematological (n = 16), breast(n = 11), oropharyngeal(n = 9) gynaecological(n = 8), other (n = 15). 18/80 died subsequent to CXR, 51/80 were on curative treatment pathway(29 palliative/end of life). 50/80 had CXR for infection, 8/80 chest pain, 7/80 disease specific follow-up, 6/80 pretreatment imaging. 27/35 of the new VF were classified as osteoporotic (8 metastatic). 23/35 had further imaging with only 9/23 mentioning VF, 8/35 had a referral for a DXA scan, 27/35 were taking calcium/vitD, 7/35 were prescribed bisphosphonates/denosumab and 0/35 were referred to a metabolic bone clinic. VFs were commonly found on CXR in this population. 77% of new fractures were osteoporotic, 63% on a curative pathway, but only 22% referred for DXA and 22% on bisphosphonates/denosumab with no patients referred to metabolic bone clinic. This highlights a significant opportunity for development of defined VF pathways.
Volume 117
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2026 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more